BioLineRx Ltd.

BioLineRx and Hemispherian announced highly encouraging new preclinical data demonstrating a strong synergistic effect between GLIX1 and PARP inhibitors in a patient-derived ovarian cancer xenograft model. The combination of GLIX1 and olaparib showed substantially better efficacy than individual drugs and comparable efficacy to cisplatin, suggesting GLIX1 can broaden PARP inhibitor use in HR-proficient ovarian cancer. BioLineRx plans to include an ovarian cancer arm in its ongoing Phase 1/2a study.

BioLineRx Ltd. reported its first quarter 2026 financial results, with a net loss of $2.6 million, a decrease from a net income of $5.1 million in the prior year. Revenues increased to $0.5 million, primarily from APHEXDA royalties. The company announced a significant milestone with the dosing of the first patient in its Phase 1/2a clinical trial of GLIX1 for glioblastoma (GBM) and presented encouraging new preclinical data for GLIX1. BioLineRx also confirmed its cash runway into the first half of 2027 with $17.4 million in cash and equivalents.

BioLineRx Ltd. and Hemispherian AS announced that new data on GLIX1, their investigational oral small molecule, will be featured at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. The data highlights GLIX1's novel mechanism of action, which involves restoring TET2 activity to induce tumor-selective DNA strand breaks, and its strong preclinical antitumor activity in glioblastoma (GBM) and other cancers. A first-in-human Phase 1/2a clinical trial for GLIX1 in GBM was initiated in March, supported by these compelling preclinical findings and observed synergistic effects with PARP inhibitors.

BioLineRx and Hemispherian announced highly encouraging new preclinical data for GLIX1, demonstrating potent anti-tumor effects in Glioblastoma (GBM). The data showed robust anti-tumor activity in orthotopic CDX GBM models and, notably, a strong effect in a Temozolomide (TMZ)-resistant patient-derived xenograft (PDX) GBM model where TMZ had no impact. These compelling results further support the recently initiated Phase 1/2a clinical trial evaluating GLIX1 for recurrent and progressive GBM and other high-grade gliomas, highlighting its potential to address a high unmet medical need.

BioLineRx Ltd. and Hemispherian AS announced the dosing of the first patient in their first-in-human, Phase 1/2a study of GLIX1 for recurrent and progressive glioblastoma (GBM) and other high-grade gliomas. GLIX1 is an oral, first-in-class small molecule designed to activate TET2 and induce tumor DNA damage. The Phase 1 part of the trial will recruit up to 30 patients, with data anticipated in H1 2027.